CAR-T cell therapy in China

Indicative band¥1.0m–1.3mindicative

Drawn from provincial schedules and institutions' published lists. Not a quote.

Typical staySeveral weeks inpatient

Your case can differ; the treating team sets the real schedule.

Decided byThe treating institution

Eligibility, technique and price are theirs to state. We translate and coordinate.

1. What CAR-T cell therapy is

CAR-T re-engineers a patient's own T-cells against certain blood cancers. In China it is available only at filed centres, and the commercial cell product itself is most of the price.

Between collection and infusion your own cells travel to a manufacturing facility and back, which is why the timeline is measured in weeks and cannot be compressed by paying more.

2. Who it is typically considered for

Assessed for certain relapsed or refractory blood cancers, after the centre's own haematology work-up. Nothing about eligibility can be promised in advance, by us or anyone.

3. How the process usually runs

01Step 1Full haematology work-up at the treating centre 02Step 2Cell collection (leukapheresis) and manufacturing wait 03Conditioning chemotherapyConditioning chemotherapy, then infusion 04Step 3Inpatient monitoring for immune-related effects

4. What sits inside, and outside, the institution's bill

Typically inside the bill

The procedure, theatre or suite time, and the treating team
Standard ward stay for the listed nights
Routine drugs and consumables during the admission
The institution's own scheduled follow-up visit

Usually billed separately

Flights, hotel and daily costs
Our translation, interpretation and coordination fees, published separately
Treatment of complications beyond the routine course
A companion's costs

What moves the total

The cell product, a published national price
Inpatient days and supportive care
Management of side effects, which varies by case

You contract with the institution directly and pay it directly. We add nothing to its bill and never handle payments owed to it.

5. Recovery and follow-up

01Step 1The first weeks after infusion are spent under close inpatient monitoring for immune reactions 02Step 2Blood counts and immune function are tracked frequently after discharge 03Step 3Long-term follow-up can often transfer to your home haematologist, with records translated

6. Common questions

Is CAR-T available to foreign patients?

At filed centres, after their own assessment, for indications within the product's approval. No intermediary can widen that.

Why is it so expensive?

The one-off engineered cell product carries a published national price that dominates everything else on the bill.

What are the risks?

Cytokine release syndrome and neurological effects are the known serious ones; managing them is why the inpatient monitoring exists. The centre explains them before consent.

Can the price be negotiated?

The product price is published and fixed. Anyone promising a discount on it is describing something that does not exist.

7. What to ask the institution

Is my subtype within the product's approved indication?
What is the all-in estimate beyond the product price?
How long is the manufacturing wait right now?

Our part, and its limits

We translate your records in full, correspond with institutions in Chinese, and interpret on site, at the rates published on the fees page. We do not give medical advice, do not recommend one institution over another, and never handle payments owed to any hospital. Whether this procedure is right for you is a question only the treating physicians can answer. Nothing on this page is medical advice, and no outcome is implied or promised.

Before any of this, the records

A rehabilitation plan can only be written by an institution that has read your case accurately. That is where the work starts.

Read: preparing your records →